ELVN
Neutral signalScored 2026-10-23 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Enliven Therapeutics, Inc.
- Nom
- Enliven Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $3.0B
- Employés
- 67
- PDG
- Richard A. Fair
- Site web
- https://www.enliventherapeutics.com
- Marché
- AVBPCGEMEXELINCYNUVBORIC
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 13 000 titres (~606 719,10 $ US)
- Insiders
- Garland J. Scott
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$10,767,095
Avg sell (VWAP, 90d window) $57.94 vs last close $41.49 (-28.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$9,736,488 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Liquid $61,262,771/day · 20d vol
- Last synced
-
2026-10-26 21:10:25
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-19 | Collins Helen Louise | Sell · S | 5,000 | $38.47 | $192,342 | Form 4 |
| 2026-10-19 | Hohl Benjamin | Sell · S | 6,018 | $38.48 | $231,546 | Form 4 |
| 2026-10-01 | Garland J. Scott | Sell · S | 13,000 | $46.67 | $606,719 | Form 4 |
| 2026-09-17 | Collins Helen Louise | Sell · S · 10b5-1 | 240 | $51.48 | $12,356 | Form 4 |
| 2026-09-17 | Hohl Benjamin | Sell · S · 10b5-1 | 289 | $51.49 | $14,881 | Form 4 |
| 2026-08-17 | Collins Helen Louise | Sell · S · 10b5-1 | 1,100 | $59.35 | $65,281 | Form 4 |
| 2026-08-17 | Hohl Benjamin | Sell · S · 10b5-1 | 1,388 | $59.35 | $82,383 | Form 4 |
| 2026-08-04 | Derynck Mika K | Sell · S · 10b5-1 | 158,795 | $60.21 | $9,561,587 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-23 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ELVN presents a mixed picture: a meaningful regulatory catalyst (FDA alignment on ENABLE-2 Phase 3 design for ELVN-001) provides near-term event-driven interest, but the complete absence of revenue and deeply negative…
The first sentence of the analysis written for ELVN on 2026-10-23 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 28.66 · operating margin 0.0%
Suggested stop 37.72, nearest stored support minus 0.5 ATR(9.1% under the last close). Reward/risk to the next stored resistance is 0.12. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-14 Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage development and commercialization, as it plans to initiate the pivotal Phase 3 trial of relcobatinib before year-end BURLINGAME, Calif., Oct. 14, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Kristine Ball to its Board of Directors, effective immediately.
- 2026-10-06 Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the final design of the ENABLE-2 pivotal trial, a Phase 3 trial of relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML).
- 2026-10-06 Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) shares fell 4.5% during mid-day trading on Tuesday following insider selling activity. The company traded as low as $43.20 and last traded at $43.4350. 62,397 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 1,251,624 shares. The stock had previously
- 2026-10-02 This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- 2026-09-16 Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-03 Enliven Therapeutics to Present at Upcoming Investor Conferences BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, Sept.
- 2026-09-03 Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-competitive inhibitor, aiming for a differentiated, chronic-use profile in a sequential treatment paradigm. Phase 1 data show 61% MMR at 80 mg daily, with favorable safety and convenience for chronic administration, supporting potential in earlier-line CML settings.
- 2026-08-31 Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting, taking place September 9-12, 2026, at the George R.
- 2026-08-28 BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,359,704 shares of the company''s stock, valued at approximately $221,255,000. BlackRock Inc. owned 7.16% of Enliven Therapeutics at
- 2026-08-18 Enliven''s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 28.662 | 19.989 | 10.278 | 8.003 | 19.237 | |
| Quick Ratio | 28.662 | 19.989 | 10.278 | 8.003 | 19.237 | |
| Solvency Ratio | -6.202 | -5.574 | -2.746 | -0.234 | -3.808 | |
| Cash Ratio | 5.969 | 7.799 | 3.867 | 7.775 | 19.125 | |
| Price To Earnings Ratio | -8.415 | -11.905 | -6.886 | -2.713 | -2.839 | |
| Price To Earnings Growth Ratio | 2.651 | 1.994 | 0.103 | -0.030 | 0.107 | |
| Forward Price To Earnings Growth Ratio | 2.651 | 1.994 | 0.103 | -0.030 | 0.107 | |
| Price To Earnings Diluted Ratio | -8.415 | -11.905 | -6.886 | -2.713 | -2.839 | |
| Price To Earnings Diluted Growth Ratio | 2.651 | 1.994 | 0.103 | -0.030 | 0.107 | |
| Price To Book Ratio | 1.899 | 3.418 | 2.001 | -1.331 | 0.658 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -12.385 | -14.462 | -8.010 | -3.127 | -3.639 | |
| Price To Operating Cash Flow Ratio | -12.413 | -14.471 | -8.029 | -3.187 | -3.675 | |
| Debt To Assets Ratio | 0.001 | 0.000 | 0.001 | 0.004 | 0.001 | |
| Debt To Equity Ratio | 0.001 | 0.000 | 0.001 | -0.004 | 0.001 | |
| Debt To Capital Ratio | 0.001 | 0.000 | 0.001 | -0.004 | 0.001 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.036 | 1.051 | 1.106 | -1.084 | 1.061 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.243 | -4.599 | -2.366 | -3.302 | -3.326 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.001 | 1.002 | 1.019 | 1.010 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -176.193 | 0.000 | -182.893 | -99.310 | -120.340 | |
| Capital Expenditure Coverage Ratio | -444.943 | -1,663.455 | -411.201 | -52.413 | -100.178 | |
| Dividend Paid And Capex Coverage Ratio | -444.943 | -1,663.455 | -411.201 | -52.413 | -100.178 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.485 | -10.568 | -5.501 | -0.722 | 1.606 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 28.662 | ▲8.673 | ▲11.428 |
| Quick Ratio | 28.662 | ▲8.673 | ▲11.428 |
| Solvency Ratio | -6.202 | ▼-0.629 | ▼-2.490 |
| Cash Ratio | 5.969 | ▼-1.830 | ▼-2.938 |
| Price To Earnings Ratio | -8.415 | ▲3.490 | ▼-1.864 |
| Price To Earnings Growth Ratio | 2.651 | ▲0.657 | ▲1.686 |
| Forward Price To Earnings Growth Ratio | 2.651 | ▲0.657 | ▲1.686 |
| Price To Earnings Diluted Ratio | -8.415 | ▲3.490 | ▼-1.864 |
| Price To Earnings Diluted Growth Ratio | 2.651 | ▲0.657 | ▲1.686 |
| Price To Book Ratio | 1.899 | ▼-1.520 | ▲0.570 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -12.385 | ▲2.077 | ▼-4.060 |
| Price To Operating Cash Flow Ratio | -12.413 | ▲2.058 | ▼-4.058 |
| Debt To Assets Ratio | 0.001 | ▲0.001 | ▼-0.001 |
| Debt To Equity Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Debt To Capital Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.036 | ▼-0.015 | ▲0.402 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.243 | ▲0.356 | ▼-0.676 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▲0.002 | ▼-0.005 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -176.193 | ▼-176.193 | ▼-60.446 |
| Capital Expenditure Coverage Ratio | -444.943 | ▲1218.512 | ▲89.495 |
| Dividend Paid And Capex Coverage Ratio | -444.943 | ▲1218.512 | ▲89.495 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.484 | ▲3.084 | ▼-2.951 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $872.6M | $1.06B | $492.0M | $102.2M | $70.3M | |
| Enterprise value | $774.1M | $935.0M | $392.2M | $27.0M | -$39.5M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -11.01x | -12.78x | -6.40x | -0.84x | 2.07x | |
| EV / Free cash flow | -10.99x | -12.77x | -6.38x | -0.83x | 2.05x | |
| EV / EBITDA | -7.49x | -10.57x | -5.50x | -0.72x | 1.61x | |
| Net debt / EBITDA | 0.95x | 1.40x | 1.40x | 2.01x | 4.46x | |
| Current ratio | 28.66x | 19.99x | 10.28x | 8.00x | 19.24x | |
| Income quality | 0.68x | 0.82x | 0.86x | 0.85x | 0.77x | |
| Graham net-net | $8 | $6 | $6 | -$14 | $13 | |
| Tax burden | 100.0% | 100.3% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $458.3M | $302.2M | $240.3M | $68.0M | $104.9M | |
| Invested capital | $458.7M | $302.7M | $241.3M | $69.6M | $105.9M | |
| Return on assets | -21.8% | -27.3% | -26.3% | -45.2% | -21.8% | |
| Operating ROA | -29.8% | -35.0% | -47.0% | -39.5% | -24.3% | |
| Return on tangible assets | -21.8% | -27.3% | -26.3% | -45.2% | -21.8% | |
| Return on equity | -22.6% | -28.7% | -29.1% | 49.0% | -23.2% | |
| Return on invested capital | -26.0% | -33.7% | -33.9% | -52.5% | -23.0% | |
| Return on capital employed | -26.0% | -33.7% | -34.0% | -52.7% | -23.0% | |
| Earnings yield | -11.9% | -8.4% | -14.6% | -36.8% | -35.2% | |
| Free cash flow yield | -8.1% | -6.9% | -12.5% | -32.0% | -27.5% | |
| Capex / Op. cash flow | -0.2% | -0.1% | -0.2% | -1.9% | -1.0% | |
| Capex / Depreciation | 60.1% | 13.9% | 50.2% | 284.7% | 166.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 2996d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -2996d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years